TRANSITION SERVICES AGREEMENT By and Between Seres Therapeutics, Inc., and Nestlé Enterprises S.A. Dated as of September 30, 2024Transition Services Agreement • October 1st, 2024 • Seres Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS TRANSITION SERVICES AGREEMENT (this “Agreement”) is dated as of September 30, 2024 (the “Effective Date”), by and between Seres Therapeutics, Inc., a Delaware corporation (“Seller”), and Nestlé Enterprises S.A., a société anonyme organized under the laws of Switzerland (“Purchaser”). Seller and Purchaser are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined herein shall have the respective meanings given to them in that certain Asset Purchase Agreement, dated as of August 5, 2024 (the “Purchase Agreement”), by and between Seller and Société des Produits Nestlé S.A. (“SPN”).
CROSS-LICENSE AGREEMENTCross-License Agreement • October 1st, 2024 • Seres Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This CROSS-LICENSE AGREEMENT (this “Agreement”), effective as of September 30, 2024 (the “Effective Date”), is made by and between Seres Therapeutics, Inc., a Delaware corporation (“Seller”), and Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (“Purchaser”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 1st, 2024 • Seres Therapeutics, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of September 30, 2024 by and between Seres Therapeutics, Inc., a Delaware corporation (the “Company”), and Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (the “Investor”).
EMPLOYEE SUPPORT AGREEMENTEmployee Support Agreement • October 1st, 2024 • Seres Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This EMPLOYEE SUPPORT AGREEMENT (this “Agreement”), is made and entered into as of September 30, 2024 (the “Effective Date”) by and between Société des Produits Nestlé S.A. (“Purchaser”) and Seres Therapeutics, Inc. (“Seller” and, together with Purchaser, the “Parties” and each, individually, a “Party”). Capitalized terms not defined herein shall have the meanings set forth in the Asset Purchase Agreement, dated as of August 5, 2024 by and between Purchaser and Seller (the “Purchase Agreement”).
